natgillin/translations-raw huggingface dataset:
Particularly, a method of the present invention comprises administering to the subject a therapeutically effective amount of (a) at least one compound of Formula (I); and (b) at least one additional agent selected from a second ERR-a inverse agonist, an ERR-a antagonist, a glucokinase modulator, an anti-diabetic agent, an anti-obesity agent, a lipid lowering agent, an anti-thrombotic agent, direct thrombin inhibitor, and a blood pressure lowering agent, said administration being in any order. 
Spoj za uporabu kako je zatraženo u zahtjevu 19, naznačen time da se navedeno liječenje sastoji od davanja subjektu terapeutski učinkovite količine (a) barem jednog spoja prema zahtjevu 1; i (b) barem jednog dodatnog sredstva odabranog od ERR-qa inverznog agonista, drugog ERR-a antagonista, modulatora glukokinaze, anti-dijabetskog sredstva, sredstva protiv pretilosti, sredstva za snižavanje lipida, sredstva protiv tromboze, direktnog inhibitora trombina, te sredstva za snižavanje krvnog tlaka, a navedeno davanje je u bilo kojem redoslijedu.
A compound having the structure or a pharmaceutically acceptable salt thereof. 
Spoj naznačen time da ima strukturu [image] ili njegova farmaceutski prihvatljiva sol.
Compound for use according to any one of claims 1-13, wherein the cell proliferative disorder is a cell proliferative disorder of the lung, a cell proliferative disorder of the colon, 
Spoj za uporabu prema bilo kojem od zahtjeva 1-14, pri čemu je poremećaj stanične proliferacije hematološkog sustava odabran iz: hematološkog raka;
pressurizing the first volume, and maintaining pressure in the first volume over a predetermined period of time while the second volume is at an initial pressure and separated from the first volume; 
prvi volumen (V1) je pod tlakom, a tlak se održava u prvom volumenu tijekom unaprijed određenog vremenskog razdoblja dok je drugi volumen na početnom tlaku i odvojen je od prvog volumena,
a JNK inhibitor, which comprises an inhibitory (poly-)peptide sequence according to the following general formula: 
JNK inhibitor koji sadrži inhibirajuću peptidnu sekvencu prema sljedećoj općoj formuli
Compounds of the formula I as claimed in claims 1 to 16 in which R2, R3, R4 are H, 
Spojevi formule I u skladu s patentnim zahtjevima 1 do 16, gdje R2, R3iR4suH,
The demands on a reactive diluent can be listed as follows: 
Zahtjevi u pogledu reaktivnog sredstva za razrjeđivanje mogu se iznijeti kako slijedi:
Glatiramer acetate for use according to claim 1, wherein the tolerability of glatiramer acetate treatment in the human patient is increased by reducing the frequency of an immediate post injection reaction or an injection site reaction. 
Glatiramer acetat za uporabu prema bilo kojem od patentnih zahtjeva 1-7, naznačen time, da smanjuje učestalost trenutne reakcije nakon injekcije u odnosu na dnevno supkutano davanje od po 20 mg glatiramer acetata.
The pharmaceutically acceptable composition of any one of clauses (1)-(9), further comprising an agent that inhibits the formation of oxidation products. 
Farmaceutski prihvatljiv tekući sastav iz bilo kojeg zahtjeva 1 do 3, nadalje sadržeći agent koji inhibira stvaranje produkata oksidacije.
Holder according to any of claims 1 - 4, in the receiving space a stack of at least three right angled cards, mutually registered, with substantially identical dimensions and each with a first side and an opposite second side, and the friction element in retaining engagement, in the direction of sliding out the card opening, with the to the friction element facing side of each card and the card sideways preloading such that the second side of each card is pressed against and retained by the side of the receiving space, while the distance between the first and second side of the one card is unequal to the same distance of a different card in the stack. 
Držač u skladu s bilo kojim od patentnih zahtjeva 1 - 4, nalazi se u prijemnom prostoru snop od najmanje tri karte pod pravim kutom, međusobno registrirane, uglavnom jednakih dimenzija i svaka s prvom stranom i suprotnom drugom stranom, a element trenja je u zadržavajućem zahvatu, u smjeru klizanja otvora kartice, s elementom trenja okrenutim prema strani svake kartice i bočne kartice prednalažući tako da je druga strana svake kartice pritisnuta i zadržana sa strane prostora za prijem, dok je udaljenost između prve i druge strane jedne kartice nejednaka u odnosu prema istoj udaljenosti od drugačije kartice u snopu.
passing the composition through an ion exchange membrane, wherein the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pI of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and the at least one contaminant, and 
propuštanje sastava kroz membranu kationske izmjene, pri čemu monoklonsko protutijelo i membrana imaju suprotne naboje, uz radne uvjete koji obuhvaćaju pufer koji ima pH od oko 1 do oko 5 pH jedinica ispod pI-vrijednosti od monoklonskog protutijela i provodljivost koja je ≤ od oko 40 mS/cm, što uzrokuje da membrana veže monoklonsko protutijelo i najmanje jedan kontaminant, i
The method of embodiment 1 or 5, wherein the gene expression profile for the test sample is obtained using reverse transcription and real-time quantitative polymerase chain reaction (qPCR) with primers specific for each of said intrinsic genes. 
(1i) profil ekspresije gena za ispitivani uzorak se dobiva obratnom transripcijom i kvantitativnom lančanom reakcijom polimeraze u realnom vremenu (qPCR), uz početnice specifične za svaki od navedenih intrinzičnih gena; ili
The compound for use claim 14, wherein inflammatory diseases are selected from rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases, pancreatitis, peripheral neuropathy, multiple sclerosis (MS) and inflammation associated with cancer. 
Uporaba prema patentnom zahtjevu 12, pri čemu su inflamatorne bolesti izabrane od reumatoidnog artritisa, osteoartritisa, ankiloznog spondilitisa, psorijatičnog artritisa, kronične opstruktivne bolesti pluća (COPD), inflamatornih bolesti crijeva, pankreatitisa, periferne neuropatije, multiple skleroze (MS) i inflamacije povezane sa karcinomom.
The method of any one of claims 1 to 14, wherein said test sample is selected from the group consisting of a biological sample, an environmental sample, a chemical sample, a pharmaceutical sample, a food sample, an agricultural sample, and a veterinary sample, wherein optionally the biological sample selected from the group consisting of blood, whole blood, leukocytes, peripheral blood mononuclear cells, plasma, serum, sputum, breath, urine, semen, saliva, meningeal fluid, amniotic fluid, glandular fluid, lymph fluid, nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate, cells, a cellular extract, stool, tissue, a tissue extract, a tissue biopsy, and cerebrospinal fluid, preferably plasma or serum. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time, da je navedeni uzorak za testiranje odabran iz skupine koju čine: biološki uzorak, uzorak iz okoliša, kemijski uzorak, farmaceutski uzorak, prehrambeni uzorak, poljoprivredni uzorak 1 veterinarski uzorak, pri čemu je biološki uzorak prema potrebi odabran iz skupine koju čine: krv, sveukupna krv, leukociti, periferne mononuklearne krvne stanice, plazma, serum, pljuvačka, dah, urin, sperma, slina, meningna tekućina, plodna voda, tekućina iz žlijezde, limfna tekućina, bris iz dojke, bris iz bronhija, sinovijalna tekućina, bris iz zgloba, stanice, stanični ekstrakt, stolica, tkivo, ekstrakt tkiva, biopsija tkiva i cerebrospinalna tekućina, a poželjno je plazma ili serum.
This ensures that the zirconia is transformed from the amorphous state into the tetragonal phase. 
To osigurava da je cirkonijev oksida transformiran iz amorfnog stanja u tetragonsku fazu.
The method of embodiment (3), wherein said disease or condition is selected from the group consisting of neuropathic pain, inflammatory pain, visceral pain, cancer pain, dental pain, chemotherapy pain, trauma pain, surgical pain, labor pain, neurogenic bladder, ulcerative colitis, chronic pain, persistent pain, peripherally mediated pain, centrally mediated pain, chronic headache, migraine headache, sinus headache, tension headache, phantom limb pain, peripheral nerve injury, and combinations thereof. 
Spojevi namijenjeni upotrebi u skladu s patentnim zahtjevom 3, naznačeni time što se navedena bolest ili stanje bira iz skupine koju čine neuropatska bol, upalna bol, visceralna bol, bol uzrokovana rakom, zubobolja, bol uzrokovana kemoterapijom, traumatska bol, bol uzrokovana kirurškim zahvatom, porođajna bol, neurogeni mokraćni mjehur, ulcerozni kolitis, kronična bol, trajna bol, periferno posredovana bol, centralno posredovana bol, kronična glavobolja, migrenska glavobolja, sinusna glavobolja, tenzijska glavobolja, bol u fantomskom udu, ozljeda perifernog živca, te njihove kombinacije.
The alternative sidechain of Formula 45 has the following structure: Formula 45 may be formed from the structure of Formula 36 (above) according to the following reaction: Here, the BOM-acid, Formula 36, (3.8g, ~10.0mmol) was dissolved in DCM (30mL), stirred and cooled in an ice-water bath at 0ºC under N2. 
Fomdo 35 Forda 45 Ovdje je BOM-kiselina, formula 36 (3.8 g, -10.0 mmol) bila otopljena u DCM (30 mL), izmiješana i ohlađena u kupelji led-voda kod 0*C pod N».
After stirring at room temperature for 18h the reaction was incomplete and another 14 mmol of sodium cyanoborohydride was added. 
Nakon miješanja na sobnoj temperaturi kroz 18 sati reakcija još nije gotova, pa se dodaje narednih 14 mmol natrij cijanoborohidrida.
A compound selected from 
Spoj izabran od
contacting at temperatures between room temperature and 4°C in a buffered aqueous solution of pH 5.5-8 an aqueous suspension comprising maleimide-functionalized hydrogel microparticles with a solution comprising the exendin-linker reagent of claim 17, wherein the chemical functional group of L2* comprises a thiol group, resulting in an exendin-linker-hydrogel conjugate; 
dovođenje u kontakt pri temperaturama između sobne temperature i 4°C u puferiranoj vodenoj otopini uz pH 5.5-8 vodene suspenzije koja sadrži mikročestice hidrogela funkcionalizirane maleimidom s otopinom koja sadrži reagens eksendin-spojnica prema patentnom zahtjevu 16, pri čemu kemijska funkcionalna skupina L2* sadrži tiolnu skupinu, što rezultira konjugatom eksendin-spojnica-hidrogel;
Use according to claim 1 wherein the parasitic invertebrate pest is a fly, mosquito, mite, tick, louse, flea, true bug or maggot. Use according to claim 7 wherein the animal to be protected is a cat or dog and the parasitic invertebrate pest is a flea, tick or mite. 
ili N-oksida ili njihovih soli, za uporabu u zaštiti životinja od parazitskih nametnika beskralješnjaka, pri čemu se tvar primjenjuje oralno, životinja koju treba zaštititi je mačka ili pas, a parazitski nametnik beskralješnjak je buha, krpelj ili šugarac.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-B-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 14, wherein said anti-CTLA4 is administered about every three weeks. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 14, gdje je rak sitnostanični rak pluća.
The solution was then diluted with ethanol and added drop-wise to a 1.5 M NH3 solution. 
Otopina je razrijeđena etanolom i dokapana je 1.5 M otopina NH:;.
X is selected from the group consisting of NR26, O and S; 
X se izabire iz skupine koja obuhvaća NR, Oi $; t>&
A system 10 (such as shown in Figure 1 or 2) could be mounted on a frame 120 that has connections to the three arms 122, 124L, and 124R of a three-point hitch of tractor 126. 
Sustav 10 (kako je prikazan na slici 1 ili 2) može se postaviti na jedan okvir 120 koji je povezan s tri kraka 122, 124L i 124R spojnice traktora 126 s tri priključne točke.
X is N or CH; and m is 0-2; n is 0-2; or a pharmaceutically acceptable salt thereof. 
XjeNili CH;i m je 0-2; nje 0-2; ili njegova farmaceutski prihvatljiva sol.
an antigen-specific targeting domain; 
antigen-specifičnu ciljajuću domenu;
The fine suspension is cooled down to 0° and 11.4 ml diisopropylcarbodiimide added. 
Fina suspenzija se ohladi na O "C i zatim se doda 11, 4 ml diizopropilkarbodiimida.
The method of claim 2, wherein the nonionic polymer is hydroxyethylcellulose. 
Polimerni hidrogel u skladu s patentnim zahtjevom 2, naznačen time da je neionski polimer hidroksietilceluloza.
The end point of the curing step is defined to be (1) the point in time when the heating is stopped or at least reduced and the temperature of the extended release matrix formulations subsequently drops below the curing temperature by more than about 10° C. and/or below the lower limit of the softening temperature range of high molecular weight polyethylene oxide, for example below about 62° C. in a plateau-like temperature profile or (2) the point in time when the temperature of the extended release matrix formulations drops below the curing temperature in a parabolic or triangular temperature profile. 
. Postupak prema zahtjevu 15, naznačen time da je temperatura koraka c) ciljana temperatura formulacije matrice s produljenim otpuštanjem i gdje korak stvrdnjavanja započinje kada temperatura formulacije matrice s produljenim otpuštanjem dosegne navedenu temperaturu i korak stvrdnjavanja završava ili kada se zaustavi zagrijavanje ili kada je barem smanjeno te izlazna temperatura zraka naknadno pada ispod navedene temperature za više od oko 10 *C ili ispod oko 62 *C, u temperaturnom profilu nalik platou ili kada temperatura formulacije matrice s produljenim otpuštanjem padne ispod navedene temperature u paraboličnom ili trokutastom temperaturnom profilu.
To prevent leakage of coolant or lubricant, each clutch pin 122 may be sealed by an O-ring 126 and may be retained in place by a snap ring 128 or other suitable arrangement. As shown in FIGS. 
Kako bi se spriječilo curenje sredstva za hlađenje ili podmazivanje, svaki zahvatni zubac (122) može biti zabrtvljen pomoću O-prstena (126), i može se zadržati na mjestu pomoću zahvatnog prstena (128) ili slične odgovarajuće izvedbe.
In particular, the cursor 7 divides the guide 6 into a first and a second chamber 27, 37, each of which has a volume that is variable according to the position assumed by the cursor 7 within the guide itself. 
Klizač 7 naročito dijeli vodilicu 6 na prvu i drugu komoru 27, 37 od kojih svaka ima volumen koji se može mijenjati ovisno o položaju koji zauzima klizač 7 unutar same vodilice.
The present invention also relates to procedures for the preparation of said compounds, their use as medicaments, in particular as atypical anti-psychotics and to pharmaceutical compositions containing them. 
Ovaj izum odnosi se također na postupke za dobivanje spomenutih spojeva, njihovu uporabu kao lijekova, posebice kao atipičnih antipsihotika te na farmaceutske pripravke koji ih sadrže.
In a preferred embodiment, the invention provides an antibody or antigen-binding fragment thereof, which binds human IL-6 receptor (SEQ ID NO:1) with a KD of about 500 pM or less, as measured by surface plasmon resonance. 
Antitijelo ili njegov fragment koji se vože na antigen, koji se specifično veže na humani interleukin-6 receptor (hIL6R) s konstantom Kp od 500 pM ili manjom izmjereno površinskom plazmonskom rezonancijom, naznačeno time, da CDR teškog lanca i CDR lakog lanca sadržavaju:
the associator (252) is configured to sequentially associate the sequentially extracted first-type syntax elements to the positions of the transform coefficient block in a scan order among the positions of the transform coefficient block, which depends on the positions of the significant transform coefficients indicated by previously extracted and associated first-type syntax elements. 
Uređaj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je pridruživač (252) konfiguriran tako, da predodređeni red skeniranja ovisi od pozicija signifikantnih koeficijenata transformacije koji su prikazani putem prethodno izvučenih 1 pridruženih elemenata sintakse prvog tipa.
2 to 5 further comprising a humectant which is selected from a group comprising Glycerin, Sorbitol, Propylene Glycol and the like, or any combination thereof, and added in an amount from about 5% (w/w) to 50% (w/w). 
Medicinska krema prema patentnim zahtjevima 1 1 3 do 6, naznačena time, da nadalje sadrži ovlaživač koji se odabire iz skupine koja sadrži glicerin, sorbitol, propilenglikol 1 slične, ili bilo koju njihovu kombinaciju 1 dodaje u količini od oko 5% (tež.) do 50% (tež.).
42], and 90° scattering is used for turbidity measurements. 
42), a 90" raspršenje se koristi za mjerenja zamućenosti.
A composition for the use according to claim 1 or 2 wherein the average particle size of the buprenorphine is less than 20 µm. 
Supstanca prema patentnom zahtjevu 2 pri čemu je prosječna veličina čestice buprenorfina manja od 10 µm.
A pharmaceutical composition according to claims 16, wherein the nanoparticle is a targeted nanoparticle containing a signaling motif. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 16, naznačen time, da je nanočestica ciljana nanočestica koja sadržava signalni motiv.
that the first gear mechanism (6a) and the second gear mechanism (6b) are arranged in parallel with each other on opposite sides of the base part (4). 
- pri čemu su prvi stupanj prijenosa (6a) i drugi stupanj prijenosa (6b) raspoređeni paralelno jedan s drugim na suprotnim stranama temeljnog dijela (4).
For 1 mg—10% Nicotine Solution: Dispense the nicotine into a tared bucket. 
Za 1 mg-10% otopine nikotina: Staviti nikotin u menziranu kantu.
The immunogenic compound according to claim 5, wherein the said linker moiety is the reaction product of a linker agent having two reactive groups with both CRM197 and a peptide of formula (I). 
Imunogeni spoj prema zahtjevu 4, naznačen time da navedena skupina premosnice je produkt reakcije sredstva premosnice koje ima dvije reaktivne skupine s oba CRM197 i peptidom s formulom (VIa) ili (VIb).
The antibody molecule composition according to one of the claims 19 to 33, wherein said antibody has a higher galactosylation degree with at least a 5% higher amount of G2 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of the antibody molecules in said antibody molecule composition than the same amount of antibody molecules of at least one antibody molecule composition of the same antibody molecule isolated from ATCC No. 
Pripravak s molekulom protutijela u skladu s jednim od patentnih zahtjeva 19 do 33, naznačen time što navedeno protutijelo ima veći stupanj galaktoziliranja najmanje 5% većom količinom G2 struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u HR P20150307 T1 molekuli protutijela kod molekula protutijela u navedenom pripravku s molekulom protutijela nego ista količina molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
The controlled release formulation of claim 1, wherein the PLG copolymer material is prepared from a starting PLG copolymer, without a step of hydrolysis of a higher molecular weight PLG copolymer material, by dissolving the starting PLG copolymer in a solvent, precipitating the PLG copolymer material with a non-solvent, and collecting the precipitated copolymer material. 
PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1, gdje uklonjena frakcija kopolimera je oko 5% do oko 10% po masi od zbira masa uklonjene kopolimerne frakcije i PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja.
The holder according to claim 1, wherein the ejector arm can deflect at least 0.35 or at least 0.5 millimeter, such value being on top of the typical fabrication tolerances of the assembled card holder. 
Držač u skladu s patentnim zahtjevom 1, naznačen time što ručica izbacivača može odmjeriti najmanje 0,35 ili najmanje 0,5 milimetara, pri čemu se ta vrijednost nalazi iznad tipičnih tolerancija izrade sastavljenog držača kartice.
Vegetable fat blend according to any one of the preceding claims, containing from 15-55 wt.% of triglycerides selected from the group consisting of HHU triglycerides, HUH triglycerides, HHH triglycerides and combinations thereof, wherein H represents palmitic acid or stearic acid and wherein U represents oleic acid, linoleic acid or linolenic acid. 
Smjesa biljnih masti u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što sadrži 15-55%, težinski, triglicerida, koje se bira iz skupine koju čine HHU trigliceridi, HUH trigliceridi, HHH trigliceridi i njihove kombinacije, wherein H prestavlja palmitinsku ili stearinsku kiselinu, a U prestavlja oleinsku, linoleinsku ili linolensku kiselinu.
The antibody of claim 1, wherein the VL CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO:7; the VL CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO:8; the VL CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO:9; the VH CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO:10; the VH CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO:11; and the VH CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO:12. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što VL CDR1 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:7; VL CDR2 sadrži ili ga čim aminokiselinski slijed iznijet u SEQ ID NO:8; VL CDR3 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:9; Vag CDRI sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:10; Vg CDR2 sadrži ili ga čini aminokiselinski slijed iznijetu SEQ ID NO:11; 1 Va CDR3 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO: 12.
a replacement at the endogenous mouse k immunoglobulin light chain variable region locus of all endogenous mouse k immunoglobulin light chain variable region gene segments with a rearranged human Vk1-39/J gene segment, a rearranged human Vk3-20/J gene segment, or a combination thereof, wherein the human gene segment is operably linked to an endogenous mouse k constant gene and wherein the mouse lacks an endogenous mouse k immunoglobulin light chain variable region locus that is capable of rearranging and forming a gene that encodes a mouse k variable region; and, 
Uporaba u skladu s patentnim zahtjevom 12, naznačena time, da stanica sadržava: (a) genski odsječak varijabilne regije lakog lanca humanog imunoglobulina koji kodira varijabilnu domenu lakog lanca humanog imunoglobulina izvedenu iz humanog segmenta gena VK1-39JK, pri čemu je genski odsječak varijabilne regije lakog lanca humanog imunoglobulina spojen izravno ili preko povezivača, na genski odsječak nepromjenjive regije lakog lanca humanog imunoglobulina, čime se dobiva gen koji kodira laki lanac humanog imunoglobulina;
Such substances preferably will be composed of carbon, hydrogen and oxygen, but they may include other materials. 
Takve supstance će poželjno bici sastavljene od ugljika, vodika 1 kisika, ali mogu uključivati druge materijale.